scholarly journals CV10 COST-EFFECTIVENESS OF LOVASTATIN, CHOLESTYRAMINE AND GEMFIBROZIL FOR THE PRIMARY PREVENTION OF CORONARY HEART DISEASE THROUGH CHOLESTEROL REDUCTION IN CATALONIA, SPAIN

2003 ◽  
Vol 6 (6) ◽  
pp. 630
Author(s):  
P Plans-Rubió ◽  
J Rovira
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
Cholesterol Reduction

Primary prevention of cardiovascular disease: Cost-effectiveness comparison

2007 ◽  
Vol 23 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Oscar H. Franco ◽  
Arno J. der Kinderen ◽  
Chris De Laet ◽  
Anna Peeters ◽  
Luc Bonneux
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Heart Disease ◽  
Smoking Cessation ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
Risk Reduction ◽  
Cost Effective ◽  
Life Years ◽  
Prevention Of Cardiovascular Disease

Objectives: The aim of this study was to evaluate the cost-effectiveness of four risk-lowering interventions (smoking cessation, antihypertensives, aspirin, and statins) in primary prevention of cardiovascular disease.Methods: Using data from the Framingham Heart Study and the Framingham Offspring study, we built life tables to model the benefits of the selected interventions. Participants were classified by age and level of risk of coronary heart disease. The effects of risk reduction are obtained as numbers of death averted and life-years saved within a 10-year period. Estimates of risk reduction by the interventions were obtained from meta-analyses and costs from Dutch sources.Results: The most cost-effective is smoking cessation therapy, representing savings in all situations. Aspirin is the second most cost-effective (€2,263 to €16,949 per year of life saved) followed by antihypertensives. Statins are the least cost-effective (€73,971 to €190,276 per year of life saved).Conclusions: A cost-effective strategy should offer smoking cessation for smokers and aspirin for moderate and high levels of risk among men 45 years of age and older. Statin therapy is the most expensive option in primary prevention at levels of 10-year coronary heart disease risk below 30 percent and should not constitute the first choice of treatment in these populations.

scholarly journals Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke

Circulation ◽  
2017 ◽  
Vol 136 (12) ◽  
pp. 1087-1098 ◽  
Author(s):  
David J. Heller ◽  
Pamela G. Coxson ◽  
Joanne Penko ◽  
Mark J. Pletcher ◽  
Lee Goldman ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
The Impact ◽  
Statin Use

Cost-Effectiveness Analysis for Statin Therapies in the Primary Prevention of Coronary Heart Disease in Italy

2000 ◽  
Vol 20 (2) ◽  
pp. 109-121 ◽  
Author(s):  
Patrizia Berto ◽  
Vicky Munro ◽  
Antonio Gaddi ◽  
Cristina Negrini ◽  
John Hutton ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary Prevention

2017 ◽  
Vol 39 (4) ◽  
pp. 804-818.e3 ◽  
Author(s):  
Stephanie R. Earnshaw ◽  
Cheryl L. McDade ◽  
YiFang Chu ◽  
Lisa E. Fleige ◽  
John L. Sievenpiper
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
Daily Intake

Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention

2004 ◽  
Vol 18 (1) ◽  
pp. 93-96 ◽  
Author(s):  
Jan Kowalski ◽  
Lucjan Pawlicki ◽  
Joanna Grycewicz ◽  
Jan Blaszczyk ◽  
Robert Irzmanski ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Primary Prevention ◽  
Antioxidative Activity
Sign in / Sign up

Export Citation Format

Share Document